Abstract 1736P
Background
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor, with poor prognosis. Its well-known association to asbestos exposure helps to identify the population mostly affected by this disease. The aim of this study is to characterize patients with MPM in two Spanish hospitals, as well as define prognostic variables which may influence outcomes and survival.
Methods
A descriptive, retrospective analysis of 97 patients diagnosed of MPM from November 2004 to December 2020 in Regional University and Virgen de la Victoria hospitals located in Málaga, Spain, was carried out. Qualitative variables were analyzed under frequency tables, and quantitative variables in the form of mean, median, maximum, minimum and standard deviation. Overall survival (OS) was calculated from the start of therapy to death from any cause or latest check-up. Survival curves were estimated with the Kaplan–Meier method and the differences between survival curves were evaluated with the log-rank test.
Results
With a median follow-up of 14 months (range 0-193), a total of 97 patients were analyzed, median age 70 (range 23-91), 71,1% (n=69) males. A 35,1% (n=34) had a known history of asbestos exposure, 74,5% (n=70) had an ECOG 0-1, and 80,4% (n=78) had advanced disease at the moment of diagnosis, defined by TNM III-IV. Median OS was 14,4 months (CI 95% 9,9-18,9), and median progression-free survival (PFS) 10,1 months (CI 95% 7,2-13). Univariate analysis demonstrated that malnutrition, poor ECOG and first treatment received - chemotherapy versus surgery - were independent prognostic factors that predicted poor survival (p<0.05). There were no significant differences when analyzing survival in patients with anemia, thrombocytosis, high levels of LDH at diagnosis or history of smoking, as found in literature reviewed. History of smoking was found to be associated with advanced stage at diagnosis (p<0.05).
Conclusions
Our study confirms poor OS in MPM. Nutritional condition, ECOG and first treatment received were found as prognostic factors in our cohort. Further investigation with larger samples should be carried out to verify these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.